Please login to the form below

Not currently logged in
Email:
Password:

Alkopharma acquires rights to Navoban

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights.

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights. 

Alkopharma intends to commercialise the drug in more than 80 countries and will drive into new markets, such as the US, to reinforce the company's growing position globally.

Alain Bouaziz, Alkopharma's president and CEO, said the deal marked an exciting step for the company and maintained the ethical basis that the company was founded on 10 years ago.

Alkopharma acquires original molecules from large pharmaceutical companies that are no longer interested in manufacturing drugs from them, such as those used in orphan diseases. In this way, it attempts to meet patients' needs for personalised treatments for rare diseases.

A new manufacturing facility is to be built in Wallis, Switzerland, starting in January 2010, to support the company's R&D and expansion plans. It will house two units, one dedicated to the production of anti-tumour products and the other to biotech-derived products.

11th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics